Piramal Enterprises has received an approval for issue of unsecured Non-Convertible Debentures (NCDs) aggregating up to Rs 125 crore on private placement basis. The Administrative Committee constituted by the Board of Directors of the Company at its meeting held on June 23, 2017 approved for the same.
Piramal Enterprises is one of the leading players globally in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India.